Health and Human Services Secretary Robert F. Kennedy Jr. directed the Food and Drug Administration earlier in 2026 to reconsider restrictions on peptides such as BPC-157 that are widely promoted by wellness influencers

Policy, personnel, and politics of the Trump White House.

Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.